NASDAQ:MRNA (Moderna)
About MRNA
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna (NASDAQ: MRNA) Latest News

Investing Articles
2 growth shares stinking out my Stocks and Shares ISA in 2025!

Investing Articles
Moderna’s meant to be a red-hot growth stock. What on earth’s gone wrong?

Investing Articles
1 ISA mistake to avoid in 2025

Investing Articles
Down 87%, is this once-famous stock set to explode like the Rolls-Royce share price?

Investing Articles
1 exciting growth stock to buy for the long run in June
Investing Articles
1 intriguing growth stock that could send Scottish Mortgage shares above £10

Investing Articles
7 shares that Fools have been buying!

Investing Articles
After ChatGPT and Temu, what could be the biggest 2024 stock market winners?

Investing Articles
2 growth stocks I’d buy for the artificial intelligence (AI) revolution in 2024

Investing Articles
Down 49% and 71%! 2 Nasdaq stocks to buy today
Investing Articles
If I’d invested £1,000 in Moderna shares 2 years ago, here’s what I’d have now!

Investing Articles
3 stocks that could drive Scottish Mortgage shares higher in 2023
1❯